Omeros to Present at the 2016 Wedbush PacGrow Healthcare Conference
August 12 2016 - 6:00AM
Business Wire
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company
committed to discovering, developing and commercializing both
small-molecule and protein therapeutics for large-market as well as
orphan indications targeting inflammation, coagulopathies and
disorders of the central nervous system, today announced that
Gregory A. Demopulos, M.D., chairman and chief executive officer,
will present at the 2016 Wedbush PacGrow Healthcare Conference in
New York next week. The presentation is scheduled for Wednesday,
August 17, 2016, at 9:10 a.m. EDT.
The presentation will be webcast. The live and archived webcasts
can be accessed on the “Events” page of the company’s website at
www.omeros.com.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering,
developing and commercializing both small-molecule and protein
therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system. Part of its proprietary PharmacoSurgery® platform,
the company’s first drug product, OMIDRIA® (phenylephrine and
ketorolac injection) 1%/0.3%, was broadly launched in the U.S. in
April 2015 for use during cataract surgery or intraocular lens
(IOL) replacement to maintain pupil size by preventing
intraoperative miosis (pupil constriction) and to reduce
postoperative ocular pain. In the European Union, the European
Commission has approved OMIDRIA for use in cataract surgery and
lens replacement procedures to maintain mydriasis (pupil dilation),
prevent miosis (pupil constriction), and to reduce postoperative
eye pain. Omeros has clinical-stage development programs focused
on: complement-related thrombotic microangiopathies;
complement-mediated glomerulopathies; Huntington’s disease and
cognitive impairment; addictive and compulsive disorders; and
preventing problems associated with urologic surgical procedures.
In addition, Omeros has a proprietary G protein-coupled receptor
(GPCR) platform, which is making available an unprecedented number
of new GPCR drug targets and corresponding compounds to the
pharmaceutical industry for drug development, and a platform used
to generate antibodies.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160812005082/en/
Investor and Media Relations:Cook Williams Communications,
Inc.Jennifer Cook Williams, 360-668-3701jennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2024 to May 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From May 2023 to May 2024